ADALIMUMAB ADALIMUMAB (14263Q) adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices 14263Q Body System: Antineoplastic And Immunomodulating Agents > Immunosuppressants > Immunosuppressants Manner of administration:Injection General Schedule Authority Required Restriction Indication: Vision threatening non-infectious uveitis Treatment phase: Balance of Supply Quantities & Cost Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge Max qty packs: 1 Max qty units: 2 # of repeats: 0 DPMQ: $495.79 Max safety net: $25.00 General Patient Charge: $25.00 Available brands Abrilada Amgevita Hadlima Hyrimoz
